Next Article in Journal
Feasibility and Attractiveness of Indication Value-Based Pricing in Key EU Countries
Previous Article in Journal
Vaccination: Short- to Long-Term Benefits from Investment
 
 
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Essay

From Population to Public Institutions: What Needs to Be Changed to Benefit from the Full Value of Vaccination

by
Thomas Szucs
1,
Sibilia Quilici
2,* and
Marina Panfilo
3
1
European Center of Pharmaceutical Medicine, Institute of Pharmaceutical Medicine, University of Basel, Basel, Switzerland
2
Sanofi Pasteur MSD, Lyon, France
3
Sanofi Pasteur MSD, Roma, Italy
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2015, 3(1), 26965; https://doi.org/10.3402/jmahp.v3.26965
Submission received: 12 December 2014 / Revised: 7 April 2015 / Accepted: 7 April 2015 / Published: 12 August 2015

Abstract

The poor perception of the benefits of vaccines, and their subsequent underuse, can result in substantial economic, societal, and political burden. Adequate support and communication from health authorities and governments is essential to promote the benefits of vaccination and reduce the risk of infectious diseases outbreaks. Cost-containment policies in the vaccine procurement processes could also be a threat to the long-term sustainability of the vaccine industry and manufacturing sites in Europe. Biologicals, such as vaccines, are highly technical and complex products to manufacture and only a few industries are engaged in this activity. Developing incentives to encourage vaccine manufacturers and identifying means of taking into consideration the specificities of vaccines in economic evaluations could allow the full value of vaccination to be appreciated. In conclusion, governments, international agencies, and other stakeholders have an important role to play to help society regain confidence in vaccination and ensure that the benefits of vaccination programmes are fully recognised and valued.
Keywords: vaccination; outbreaks; value; vaccine industry; economic evaluation; vaccines complexity vaccination; outbreaks; value; vaccine industry; economic evaluation; vaccines complexity

Share and Cite

MDPI and ACS Style

Szucs, T.; Quilici, S.; Panfilo, M. From Population to Public Institutions: What Needs to Be Changed to Benefit from the Full Value of Vaccination. J. Mark. Access Health Policy 2015, 3, 26965. https://doi.org/10.3402/jmahp.v3.26965

AMA Style

Szucs T, Quilici S, Panfilo M. From Population to Public Institutions: What Needs to Be Changed to Benefit from the Full Value of Vaccination. Journal of Market Access & Health Policy. 2015; 3(1):26965. https://doi.org/10.3402/jmahp.v3.26965

Chicago/Turabian Style

Szucs, Thomas, Sibilia Quilici, and Marina Panfilo. 2015. "From Population to Public Institutions: What Needs to Be Changed to Benefit from the Full Value of Vaccination" Journal of Market Access & Health Policy 3, no. 1: 26965. https://doi.org/10.3402/jmahp.v3.26965

APA Style

Szucs, T., Quilici, S., & Panfilo, M. (2015). From Population to Public Institutions: What Needs to Be Changed to Benefit from the Full Value of Vaccination. Journal of Market Access & Health Policy, 3(1), 26965. https://doi.org/10.3402/jmahp.v3.26965

Article Metrics

Back to TopTop